Repeatability of Peripapillary Retinal Nerve Fiber Layer and Inner Retinal Thickness Among Two Spectral Domain Optical Coherence Tomography Devices

2014 ◽  
Vol 55 (10) ◽  
pp. 6536 ◽  
Author(s):  
Juliane Matlach ◽  
Martin Wagner ◽  
Uwe Malzahn ◽  
Winfried Göbel
Keyword(s):  
Optical Coherence Tomography ◽  
Nerve Fiber ◽  
Retinal Nerve Fiber Layer ◽  
Retinal Thickness ◽  
Spectral Domain ◽  
Optical Coherence ◽  
Fiber Layer ◽  
Nerve Fiber Layer ◽  
Retinal Nerve Fiber

Retinal Optical Coherence Tomography Metrics Are Unchanged in Verubecestat Alzheimer’s Disease Clinical Trial but Correlate with Baseline Regional Brain Atrophy

2021 ◽  
Vol 79 (1) ◽  
pp. 275-287
Author(s):  
Robert C. Sergott ◽  
Annaswamy Raji ◽  
James Kost ◽  
Cyrille Sur ◽  
Saheeda Jackson ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Optical Coherence Tomography ◽  
Nerve Fiber ◽  
Retinal Nerve Fiber Layer ◽  
Brain Atrophy ◽  
Retinal Thickness ◽  
Optical Coherence ◽  
Fiber Layer ◽  
Nerve Fiber Layer ◽  
Retinal Nerve Fiber

Background: We performed exploratory analyses of retinal thickness data from a clinical trial of the AβPP cleaving enzyme (BACE) inhibitor verubecestat in patients with Alzheimer’s disease (AD). Objective: To evaluate: 1) possible retinal thickness changes following BACE inhibition; and 2) possible association between retinal thickness and brain atrophy. Methods: Retinal thickness was measured using spectral-domain optical coherence tomography in a 78-week randomized placebo-controlled trial of verubecestat in 1,785 patients with mild-to-moderate AD. Changes from baseline in retinal pigment epithelium, macular grid retinal nerve fiber layer, central subfield retinal thickness, and macular grid volume were evaluated for verubecestat versus placebo. Correlation analyses were performed to investigate the potential association between macular grid retinal nerve fiber layer and central subfield retinal thickness with brain volumetric magnetic resonance imaging (vMRI) data at baseline, as well as correlations for changes from baseline at Week 78 in patients receiving placebo. Results: Verubecestat did not significantly alter retinal thickness during the trial compared with placebo. At baseline, mean macular grid retinal nerve fiber layer and central subfield retinal thickness were weakly but significantly correlated (Pearson’s r values≤0.23, p-values < 0.01) with vMRI of several brain regions including whole brain, hippocampus, and thalamus. At Week 78, correlations between retinal thickness and brain vMRI changes from baseline in the placebo group were small and mostly not statistically significant. Conclusion: BACE inhibition by verubecestat was not associated with adverse effects on retinal thickness in patients with mild-to-moderate AD. Correlations between retinal thickness and brain volume were observed at baseline. Trial registration: Clinicaltrials.gov NCT01739348 (registered December 3, 2012; https://clinicaltrials.gov/ct2/show/NCT01739348).

scholarly journals Retinal Nerve Fiber Layer Measurement Variability with Spectral Domain Optical Coherence Tomography

2012 ◽  
Vol 26 (1) ◽  
pp. 32 ◽  
Author(s):  
Jung Taeck Hong ◽  
Kyung Rim Sung ◽  
Jung Woo Cho ◽  
Sung-Cheol Yun ◽  
Sung Yong Kang ◽  
...  
Keyword(s):  
Optical Coherence Tomography ◽  
Nerve Fiber ◽  
Retinal Nerve Fiber Layer ◽  
Spectral Domain ◽  
Optical Coherence ◽  
Fiber Layer ◽  
Measurement Variability ◽  
Nerve Fiber Layer ◽  
Retinal Nerve Fiber

Retinal Nerve Fiber Layer Imaging with Spectral-domain Optical Coherence Tomography (OCT)—A Review of the Cirrus HD-OCT

2011 ◽  
Vol 04 (01) ◽  
pp. 12 ◽  
Author(s):  
Elaine To ◽  
Dennis Lam ◽  
Christopher Kai-shun Leung ◽  
◽  
◽  
...  
Keyword(s):  
Optical Coherence Tomography ◽  
Nerve Fiber ◽  
Retinal Nerve Fiber Layer ◽  
Spectral Domain ◽  
Optical Coherence ◽  
Fiber Layer ◽  
Nerve Fiber Layer ◽  
Spectral Domain Oct ◽  
Rnfl Thickness ◽  
Retinal Nerve Fiber

High-speed, high-resolution imaging of the retinal nerve fiber layer (RNFL) with spectral-domain optical coherence tomography (OCT) has become an essential tool for evaluation of glaucoma. The Cirrus HD-OCT (Carl Zeiss Meditec, Inc. Dublin, CA) is a spectral-domain OCT that provides visualization of the distribution pattern and measurement of RNFL abnormalities in a 6x6mm2optic disc region. Analysis of the RNFL thickness deviation map—a color-coded map displaying areas of RNFL abnormalities—detects glaucoma with high sensitivity and specificity. Trend analysis of average and sectorial RNFL thicknesses, and event analysis of the RNFL thickness maps and the RNFL thickness profiles can be used to detect and follow diffuse and focal RNFL progression. RNFL measurement with spectral-domain OCT could provide important information for use in formulating treatment plans and evaluating disease prognosis in the management of glaucoma.

Sign in / Sign up

Export Citation Format

Share Document